Novo Nordisk (NOVOB DC) releases 2026 sales and op. profit outlook; Sees 2026 sales at constant FX -5% to -13% (exp. -1.39%)

Novo Nordisk's FY25 results show a slight beat on both sales and EPS, highlighting the strength of its core products, particularly Wegovy.

Newsquawk StaffPublished 3 Feb 2026, 16:57 UTCOn the live feed at 16:37 UTC — 3 more headlines followed before this page went public

Newsquawk headlinesUTC

16:43

Russian President Putin says Russia's GDP up 1% in 2025

16:42

Paramount Skydance (PSKY) CEO Ellison turned down an invitation to testify before the Senate at an antitrust hearing about the proposed tie-up between Netflix (NFLX) and Warner Bros. Discovery (WBD), Bloomberg reports

16:37

Novo Nordisk (NOVOB DC) releases 2026 sales and op. profit outlook; Sees 2026 sales at constant FX -5% to -13% (exp. -1.39%)

16:34

Toyoto Motor (TM) January US sales 176.8k units, +8.1% Y/Y

16:32

US sells 6-week bills at a high rate of 3.64%, B/C 2.83x

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

FY25 results (DKK):

Sales 309.1bln (exp. 307.3bln).
EPS 23.03 (exp. 22.99).
Wegovy sales 79.1bln (exp. 78.2bln).
Net income 102.4bln.
Op. profit 127.7bln.

2026 sales and operating profit outlook

Sales and operating profit for 2026 will be positively impacted by a reversal of sales rebate provisions of USD 4.2bln related to the 340B Drug Pricing Program in the US.
2026 sales outlook reflects expectations for sales growth within International Operations and expectations for a sales decline within US Operations.
In 2026, the global GLP-1 market expansion is assumed to continue, enabling Novo Nordisk to increase patient reach and expand volumes. This is countered by lower realised prices, including the MFN ("Most Favoured Nations") agreement in the US and the loss of exclusivity for the semaglutide molecule in certain markets in International Operations.
Lastly, positive impacts related to US gross-to-net sales adjustments during 2025 are not anticipated to reoccur

Context

However, the 2026 outlook anticipates a significant sales decline in the US, primarily due to pricing dynamics and loss of exclusivity, which could hinder future growth despite benefiting from the broader GLP-1 market expansion. This mixed guidance suggests a cautious approach moving forward, indicating potential headwinds that may weigh on the stock's performance.

All markets · last 90 days

Recent headlines that moved markets

ENERGY/3 Sept · 08:03 UTC

Russian President Putin says that Russia and Ukraine should agree first; he notes that there is an opportunity to reach a peace agreement.

with Brent Nov, after we published−1.3%

Energy prices fell following Russian President Putin's more conciliatory comments.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

ENERGY/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

- Brent (V6), after we published+1.2%

METALS/1 Sept · 08:06 UTC

Two oil supertankers were reportedly hit by projectiles in the Strait of Hormuz, reports citing Marisks suggest (details light)

Spot Gold, after we published−1.0%

FX/28 Aug · 14:00 UTC

Fed Chair Warsh says Fed has more work to do unless confident underlying inflation is moving towards 2% objective

DXY, after we published+0.5%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.